CTX110, targeting CD19, is currently being evaluated in the Phase 1 CARBON trial for relapsed/refractory non-Hodgkin’s lymphoma (r/r NHL), demonstrating a 67% overall response rate (ORR) at the highest dose, with no GvHD despite significant HLA mismatch. Here, CD19 is linked to non-Hodgkin lymphoma.